Roche’s board of directors have lined up Dr Claudia Süssmuth Dyckerhoff to replace Professor Dr Beatrice Weder di Mauro, who has decided to not stand for re-election at the company’s annual general meeting in March.
Weder di Mauro has been a member of the board since 2006 and also served on its audit committee.
Dyckerhoff is currently senior partner at McKinsey & Company and sector leader Asia health services and systems.
Christoph Franz, chairman of Roche, said: “As a member of the board and the audit committee, Beatrice Weder di Mauro has made significant contributions to Roche’s success with her broad expertise in economics.”
He added: “I am delighted with our nomination of Claudia Süssmuth Dyckerhoff for election as a new member of the board. She is a leader with extensive international experience in strategic consultancy in the healthcare industry, especially in Asian growth markets.”